Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05246995 | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 60 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03994484 |
| Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets |
| unknown |
| Phase 1 |
| 44 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY |
| 1 |
| Feb 10, 2022 |
| clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT05118841 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05194709 | Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors | unknown | Early Phase 1 | 40 | Wuxi People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04471675 | Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel | unknown | Phase 1 | 208 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04811118 | The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere | unknown | Phase 1 | 27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05114915 | A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors | unknown | Phase 1 | 144 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05136937 | A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05212896 | An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 90 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05212987 | Study of FCN-098 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 43 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02675946 | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | unknown | Phase 1 | 72 | Curegenix Inc.INDUSTRY | 2 | Jan 26, 2022 | clinicaltrials |
| NCT04679038 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 222 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05125523 | A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 264 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05122572 | RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Wuxi People's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT04122339 | MAX-10181 Given Orally to Patients With Advanced Solid Tumor | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04183764 | MAX-40279-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05196360 | MAX-10181 in Patients With Advanced Solid Tumor(PD-L1) | unknown | Phase 1 | 80 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05153096 | Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 410 | NovaRock Biotherapeutics, LtdINDUSTRY | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05172856 | A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 110 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 29, 2021 | clinicaltrials |
| NCT04671654 | Systematic Evaluation of Human Explant Model Systems Engineering(SEEDLING) | unknown | — | 100 | University Hospital HeidelbergOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04990739 | Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | MetaboMed IncOTHER | 2 | Dec 17, 2021 | clinicaltrials |
| NCT05154604 | A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours | unknown | Phase 1 | 156 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | unknown | Phase 2 | 180 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05149027 | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors | unknown | Phase 1 | 67 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Dec 8, 2021 | clinicaltrials |
| NCT04941339 | A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 | 74 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05046847 | A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05049265 | Clinical Study of JS007 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03710265 | SHR-1701 in Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 206 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03662815 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03869632 | First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors | unknown | Phase 1 | 36 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05119933 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | unknown | Phase 1 / Phase 2 | 55 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05115500 | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) | unknown | Phase 2 | 55 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04719065 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor | unknown | Phase 1 | 90 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT05097781 | Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | unknown | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05072522 | A Study of SKLB1028 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 98 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03929185 | Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors | unknown | — | 100 | University Hospital of FerraraOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05060263 | A Study of of HOT1030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Sep 29, 2021 | clinicaltrials |
| NCT05058937 | A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre(BALLETT) | unknown | N/A | 936 | The Belgian Society of Medical OncologyOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05058352 | A Study of HS269 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04981691 | Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors(Amaretto) | unknown | Phase 1 | 12 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04859777 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | unknown | Phase 1 | 70 | Monopteros Therapeutics Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03973450 | Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia(EpidemioPIT) | unknown | — | 400 | Neuromed IRCCSOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04972422 | A Phase 1b Study of ZN-c3 in Chinese Subjects | unknown | Phase 1 | 38 | Zentera Therapeutics HK LimitedINDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT05020119 | Neoantigen-expanded Autologous Immune Cell Therapy | unknown | Phase 1 | 9 | Chang Gung Memorial HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2022source: clinicaltrials